Category Archives: Uncategorized

Radikal Therapeutics awarded funding by Health and Human Services (HHS) for development of inhaled chlorine antidote R-107

October 10, 2016

Radikal Therapeutics announces hiring of C. Edwin Garner, Ph.D. as Director of Metabolism and Pharmacokinetics

January 1, 2014

Radikal Therapeutics awarded Phase 1 Small Business Innovation grant by the National Institutes of Health for investigation of a novel therapy of Ventilatory Trauma

September 16, 2013

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Lung Transplantation

August 28, 2013

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of bronchopulmonary dysplasia

August 3, 2013

Radikal Therapeutics awarded Phase 2 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Limb Ischemia Reperfusion Injury

July 23, 2013

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of bronchopulmonary dysplasia

July 11, 2013

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of inflammatory bowel disease

April 29, 2013

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Diabetes Mellitus

February 19, 2013

Radikal Therapeutics announces hiring of Zsuzsanna Zsellenger, M.D., Ph.D. as Director of Investigational Pathology

February 18, 2013

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Radiocontrast Nephropathy

November 19, 2012

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Autoimmune Arthritis

August 24, 2012

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Lung Transplantation

August 20, 2012

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Lung Transplantation

August 10, 2012

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of inflammatory bowel disease

August 8, 2012

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Smoke Inhalation and Burn Injury

July 31, 2012

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Peripheral Hypertension

April 30, 2012

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Endotoxemia

April 30, 2012

Radikal Therapeutics awarded Phase 1 Small Business Innovation Research grant by the National Institutes of Health for investigation of a novel therapy of Traumatic Brain Injury

December 23, 2011

Radikal Therapeutics awarded Counteract grant by the National Institutes of Health for investigation of a novel therapy of Acute Chlorine Inhalation Injury

September 21, 2011

« Older Entries

home contact
Address: 8 Solviva Road, West Tisbury, MA 02575-1626, USA
Email: info@radikalrx.com
RTX - Radikal Therapeutics | www.radikalrx.com © All Rights Reserved
©  Web Design by Willow Management